Results for tag: "Non Hodgkin Lymphoma"

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the immune system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. NHL is the seventh most common cancer in the United States and the fifth most common cause of cancer death. Treatment options for NHL include chemotherapy, radiation therapy, targeted therapy, and stem cell transplantation. The oncology market is a rapidly growing field, with NHL being a major contributor. The market is driven by the increasing prevalence of NHL, the development of new treatments, and the increasing demand for personalized treatments. Additionally, the increasing focus on early diagnosis and the availability of new technologies are expected to drive the market growth. Companies in the NHL market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more